revolade
novartis europharm limited - eltrombopag - purpura, trombocitopenija, idiopatinė - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ir 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ir 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.
ciprinol
krka, d.d., novo mesto - ciprofloksacinas - infuzinis tirpalas - 400 mg/200 ml; 200 mg/100 ml; 100 mg/50 ml; 10 mg/ml; 250 mg; 500 mg - ciprofloxacin
ciprofloxacin sandoz
sandoz d.d. - ciprofloksacinas - plėvele dengtos tabletės - 500 mg - ciprofloxacin
cifran
sun pharmaceutical industries europe b. v. - ciprofloksacinas - plėvele dengtos tabletės - 500 mg - ciprofloxacin
alendronic acid/colecalciferol mylan
mylan pharmaceuticals limited - alendrono rūgštis/kolekalciferolis - tabletės - 70 mg/2800 tv - alendronic acid and colecalciferol
alendronic acid/colecalciferol mylan
mylan pharmaceuticals limited - alendrono rūgštis/kolekalciferolis - tabletės - 70 mg/5600 tv - alendronic acid and colecalciferol
torasemide hexal
hexal ag - torazemidas - tabletės - 200 mg; 50 mg; 100 mg - torasemide
visannette
bayer ag - dienogestas - tabletės - 2 mg - dienogest
sawis
gedeon richter plc - dienogestas - tabletės - 2 mg - dienogest
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - vaistai nuo obstrukcinių kvėpavimo takų ligų, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).